GSK plc ADR Stock
Price
Target price
€37.00
€37.00
-0.540%
-0.2
-0.540%
€35.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
GSK plc ADR shows a slight decrease today, losing -€0.200 (-0.540%) compared to yesterday.
Our community is currently high on GSK plc ADR with 4 Buy predictions and 0 Sell predictions.
However, we have a potential of -5.41% for GSK plc ADR as the target price of 35 € is below the current price of 37.0 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of GSK plc ADR in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -0.540% | -3.646% | -5.128% | 10.119% | 10.119% | -6.329% | -16.384% |
| Astrazeneca ADR | 0.000% | -0.769% | 5.738% | -5.839% | 4.878% | 50.000% | - |
| Bayer AG ADR | 3.880% | -5.634% | 6.349% | -55.034% | -22.093% | -50.735% | -55.629% |
| Novo Nordisk A/S ADR | -0.430% | -1.702% | -4.938% | -23.256% | 23.134% | 90.594% | 168.605% |
Comments
GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
GSK is a remedy for the winter investment blahs
GSK (NYSE: GSK) is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to
